Previous 10 | Next 10 |
2024-06-07 10:57:58 ET Summary Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter o...
2024-06-07 04:22:02 ET More on Alvotech Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech and Dr. Reddy’s collaborate for commercialization of denosumab Teva, Alvotech launch biosimilar against AbbVie’s Humira Read the ...
REYKJAVIK, Iceland, June 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a strategic refinancing transaction. The financing,...
REYKJAVIK, Iceland, May 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Healthcare Conference in New York on June 5-6, ...
2024-05-24 07:00:07 ET Balaji Prasad from Barclays issued a price target of $22.00 for ALVO on 2024-05-24 05:26:00. The adjusted price target was set to $22.00. At the time of the announcement, ALVO was trading at $13.58. The overall price target consensus is at $15.00 w...
2024-05-22 12:55:26 ET Alvotech (ALVO) Q1 2024 Earnings Conference Call May 22, 2024 8:00 AM ET Company Participants Benedikt Stefansson - Senior Director, Investor Relations and Global Communications Robert Wessman - Founder, Chairman and Chief Executive Officer ...
2024-05-22 00:48:12 ET More on Alvotech Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech and Dr. Reddy’s collaborate for commercialization of denosumab Teva, Alvotech launch biosimilar against AbbVie’s Humira Seeking Alp...
Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high co...
2024-05-21 16:00:07 ET Balaji Prasad from Barclays issued a price target of $20.00 for ALVO on 2024-05-21 14:22:00. The adjusted price target was set to $20.00. At the time of the announcement, ALVO was trading at $13.76. The overall price target consensus is at $13.50 w...
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product Alvotech (NASDAQ: ALVO), a global biotech compa...
News, Short Squeeze, Breakout and More Instantly...
Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology 1 , dermatology and rheumatology Creates competition at earliest opportunity, enabling straightforward switching to broaden p...
REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facil...
2024-07-09 15:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...